Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Molecular classification has transformed the management of brain tumors by enabling more
accurate prognostication and personalized treatment. However, timely molecular diagnostic …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Glioblastoma multiforme (GBM) is the most common form of brain cancer and one of the
most aggressive cancers found in humans. Most of the signs and symptoms of GBM can be …

The immune system is capable of recognizing tumors and eliminates many early malignant
cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is …

Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting
immune mediators that enable anti-tumor responses within and outside the radiation field …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …

Among various gene therapy methods for cancer, suicide gene therapy attracts a special
attention because it allows selective conversion of non-toxic compounds into cytotoxic drugs …